SECOND SIGHT MEDICAL PRODUCTS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.63 USD | -3.83% |
|
-4.12% | -28.51% |
| 2022 | Vivani Medical Starts Nasdaq Trading Lower | MT |
| 2022 | Second Sight Medical Products, Inc.(NasdaqCM:EYES) dropped from NASDAQ Composite Index | CI |
Valuation
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 83.23 | 108.5 | 67.6 | 92.45 | 43.23 | 64.24 |
| Enterprise Value (EV) 1 | 72.35 | 100.7 | 63.12 | 83.73 | 42.25 | -5.119 |
| P/E ratio | -2.35 x | -3.63 x | -1.67 x | -2.6 x | -2.59 x | -6 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 20.9 x | 13.6 x | 9.8 x | 27.4 x | - | - |
| EV / Revenue | 18.2 x | 12.6 x | 9.15 x | 24.8 x | - | - |
| EV / EBITDA | -2.21 x | -3.58 x | -1.85 x | -2.77 x | -3.38 x | 0.58 x |
| EV / FCF | -5.52 x | -7.4 x | -3.82 x | -6.07 x | -3.93 x | 0.86 x |
| FCF Yield | -18.1% | -13.5% | -26.2% | -16.5% | -25.5% | 116% |
| Price to Book | 7.55 x | 14 x | 21.9 x | 12.8 x | -64.6 x | 0.94 x |
| Nbr of stocks (in thousands) | 1,760 | 2,367 | 3,181 | 5,192 | 7,706 | 13,136 |
| Reference price 2 | 47.28 | 45.84 | 21.25 | 17.81 | 5.610 | 4.890 |
| Announcement Date | 3/16/17 | 3/20/18 | 3/19/19 | 3/19/20 | 3/16/21 | 3/29/22 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Net sales 1 | 3.985 | 7.964 | 6.896 | 3.379 | - | - |
| EBITDA 1 | -32.78 | -28.15 | -34.19 | -30.2 | -12.5 | -8.863 |
| EBIT 1 | -33.21 | -28.61 | -34.62 | -30.6 | -12.67 | -8.933 |
| Operating Margin | -833.38% | -359.23% | -502.1% | -905.5% | - | - |
| Earnings before Tax (EBT) 1 | -33.18 | -28.52 | -35.09 | -33.59 | -14.88 | -8.921 |
| Net income 1 | -33.18 | -28.52 | -35.09 | -33.59 | -14.88 | -8.921 |
| Net margin | -832.6% | -358.06% | -508.9% | -994.14% | - | - |
| EPS 2 | -20.13 | -12.64 | -12.69 | -6.852 | -2.170 | -0.8155 |
| Free Cash Flow 1 | -13.1 | -13.61 | -16.51 | -13.8 | -10.76 | -5.929 |
| FCF margin | -328.69% | -170.88% | -239.42% | -408.53% | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/16/17 | 3/20/18 | 3/19/19 | 3/19/20 | 3/16/21 | 3/29/22 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 10.9 | 7.84 | 4.47 | 8.73 | 0.98 | 69.4 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -13.1 | -13.6 | -16.5 | -13.8 | -10.8 | -5.93 |
| ROE (net income / shareholders' equity) | -211% | -300% | -640% | -649% | -451% | -26.4% |
| ROA (Net income/ Total Assets) | -92.1% | -114% | -172% | -140% | -75.2% | -14.8% |
| Assets 1 | 36.01 | 24.96 | 20.42 | 23.96 | 19.79 | 60.19 |
| Book Value Per Share 2 | 6.270 | 3.280 | 0.9700 | 1.400 | -0.0900 | 5.200 |
| Cash Flow per Share 2 | 0.3000 | 0.2500 | 1.410 | 2.170 | 0.4100 | 5.300 |
| Capex 1 | 0.49 | 0.27 | 0.16 | 0.49 | 0.33 | 0.01 |
| Capex / Sales | 12.3% | 3.33% | 2.36% | 14.59% | - | - |
| Announcement Date | 3/16/17 | 3/20/18 | 3/19/19 | 3/19/20 | 3/16/21 | 3/29/22 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- EYES Stock
- Financials Second Sight Medical Products
